Loading
Adagrasib / Carcinoma, Non Small Cell Lung / Pembrolizumab · Phase 3 Trial
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
KRYSTAL-4 is a Phase 3 randomized controlled trial comparing adagrasib plus pembrolizumab plus chemotherapy to placebo plus pembrolizumab plus chemotherapy in treatment-naïve patients with KRAS G12C-mutant non-squamous NSCLC. This is a study registration; no efficacy or safety results are posted, and the trial is currently recruiting.
Phase 3, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Carcinoma, Non-Small-Cell Lung; age from 18 Years. Intervention: Adagrasib. Compared with: Placebo — Placebo Comparator. n = 630. 351 sites across 35 countries.
KRYSTAL-4 is a Phase 3 randomized controlled trial comparing adagrasib plus pembrolizumab plus chemotherapy to placebo plus pembrolizumab plus chemotherapy in treatment-naïve patients with KRAS G12C-mutant non-squamous NSCLC. This is a study registration; no efficacy or safety results are posted, and the trial is currently recruiting.
Safety and tolerability data are not yet available.
Clinical relevance depends entirely on trial completion and results reporting. This registration defines the planned comparison and endpoints but provides no evidence of efficacy or safety to inform practice.
This is a Phase 3 trial registration with no results posted; the study is actively recruiting and outcomes are not yet reported.
As stated by the source record.
Quoted from the source exactly as published.
Clinical relevance depends entirely on trial completion and results reporting. This registration defines the planned comparison and endpoints but provides no evidence of efficacy or safety to inform practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06875310). This is a study registration, not published results. Lead sponsor: Mirati Therapeutics Inc.. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 630 participants (ESTIMATED). Conditions: Carcinoma, Non-Small-Cell Lung. Interventions: DRUG: Adagrasib; DRUG: Pembrolizumab; DRUG: Carboplatin; DRUG: Pemetrexed; DRUG: Placebo; DRUG: Cisplatin. Primary outcome measures: Progression Free Survival (PFS) as Assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded Independent Central Review (BICR) , Up to 7 years; Overall Survival (OS) , Up to 7 years. Brief summary: This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.